CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
DUBLIN, Ireland, July 10, 2017 -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its second-quarter 2017 financial results will be released on Monday, Aug. 7, 2017. Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
The live webcast and a replay may be accessed at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes before the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-888-338-8373 (U.S.) or 973-872-3000 (international) to listen to the conference call. The conference ID number for the live call is 45942068. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 45942068.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Investors: Tina Ventura Senior Vice President, Investor Relations [email protected] Ruth Venning Executive Director, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Affairs & Chief Communications Officer [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
